X4 Pharmaceuticals Files 8-K for Regulation FD Disclosure

TL;DR

**XFOR just filed an 8-K for Regulation FD, expect big news soon!**

AI Summary

X4 Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, under Regulation FD Disclosure, indicating they are making a public announcement of material non-public information. This filing simply states the company's basic information, such as its address at 61 North Beacon Street, 4th Floor, Boston, Massachusetts, and its common stock trading on The Nasdaq Stock Market LLC under the symbol XFOR. For investors, this filing itself doesn't contain new financial or operational news, but rather signals that a significant disclosure is likely imminent, which could impact the stock price.

Why It Matters

This filing signals that X4 Pharmaceuticals is about to release important, previously non-public information, which could significantly affect its stock price and investor sentiment. Investors should be alert for a subsequent announcement.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the 'Regulation FD Disclosure' item indicates material news is coming, which always carries inherent market risk.

Analyst Insight

A smart investor would monitor X4 Pharmaceuticals (XFOR) closely for subsequent announcements, as this 8-K indicates material news is forthcoming that could impact the stock price. Do not make investment decisions based solely on this administrative filing.

Key Numbers

• $0.001 — par value per share (the stated par value of X4 Pharmaceuticals' Common Stock)
• 857-529-8300 — business phone number (X4 Pharmaceuticals' telephone number)

Key Players & Entities

• X4 Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where X4 Pharmaceuticals' common stock is registered
• Boston, Massachusetts (location) — the city and state of X4 Pharmaceuticals' principal executive offices
• Delaware (location) — the state of incorporation for X4 Pharmaceuticals, Inc.

Forward-Looking Statements

• X4 Pharmaceuticals will release a press release or another SEC filing containing material information. (X4 Pharmaceuticals, Inc.) — high confidence, target: 2024-01-09
• The stock price of XFOR will react to the upcoming material disclosure. (XFOR) — medium confidence, target: 2024-01-10

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market

Filing Documents

• xfor-20240108.htm (8-K) — 27KB
• 0001628280-24-000843.txt ( ) — 155KB
• xfor-20240108.xsd (EX-101.SCH) — 2KB
• xfor-20240108_lab.xml (EX-101.LAB) — 25KB
• xfor-20240108_pre.xml (EX-101.PRE) — 13KB
• xfor-20240108_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 8, 2024, X4 Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Investors" section of the Company's website at www.x4pharma.com. The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: January 8, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR